A Lupus Drug and FDA Approval

We are concerned about misinformation in the News Focus article “Lupus drug company asks FDA for second chance” (J. Couzin, 11 Feb., p. [835][1]). It is not true that the U.S. Food and Drug Administration (FDA) has rejected the medication LJP 394, which is under active development by La Jolla